<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risk categories for arterial occlusive events with ponatinib based on 2016 European Systematic COronary Risk Evaluation (SCORE) assessment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risk categories for arterial occlusive events with ponatinib based on 2016 European Systematic COronary Risk Evaluation (SCORE) assessment</h1>
<div class="graphic"><div class="figure"><div class="ttl">Risk categories for arterial occlusive events with ponatinib based on 2016 European Systematic COronary Risk Evaluation (SCORE) assessment</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Very high-risk</td> </tr> <tr> <td class="indent1">Subjects with any of the following: <ul class="decimal_heading"> <li>Documented cardiovascular disease (CVD), clinical or unequivocal on imaging.</li> <li>Documented CVD includes previous myocardial infarction (MI), acute coronary syndrome (ACS), coronary revascularization (percutaneous coronary intervention [PCI], coronary artery bypass graft surgery [CABG]) and other arterial revascularization procedures, stroke and transient ischemic attack (TIA), and peripheral arterial disease (PAD). Unequivocally documented CVD on imaging is what has been shown to be strongly predisposed to clinical events, such as significant plaque on coronary angiography or carotid ultrasound.</li> <li>DM with target organ damage such as proteinuria or with a major risk factor such as smoking, hypertension or dyslipidemia.</li> <li>Severe CKD (GFR &lt;30 mL/min/1.73 m<sup>2</sup>).</li> <li>A calculated SCORE ≥10% for 10-year risk of fatal CVD.*</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">High-risk</td> </tr> <tr> <td class="indent1">Subjects with: <ul class="decimal_heading"> <li>Markedly elevated single risk factors, in particular cholesterol &gt;8 mmol/L (&gt;310 mg/dL) (eg, in familial hypercholesterolemia) or BP ≥180/110 mmHg.</li> <li>Most other people with DM (some young people with type 1 diabetes may be at low or moderate risk).</li> <li>Moderate CKD (GFR 30 to 59 mL/min/1.73 m<sup>2</sup>).</li> <li>A calculated SCORE ≥5% and &lt;10% for 10-year risk of fatal CVD.*</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Moderate-risk</td> </tr> <tr> <td class="indent1">SCORE is ≥1% and &lt;5% for 10-year risk of fatal CVD.*</td> </tr> <tr> <td class="subtitle1_single">Low-risk</td> </tr> <tr> <td class="indent1">SCORE &lt;1% for 10-year risk of fatal CVD.*</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>SCORE: Systematic Coronary Risk Evaluation;
	CVD: cardiovascular disease;
	MI: myocardial infarction;
	ACS: acute coronary syndrome;
	PCI: percutaneous coronary intervention;
	CABG: coronary artery bypass graft surgery;
	TIA: transient ischemic attack;
	PAD: peripheral arterial disease;
	DM: diabetes mellitus;
	GFR: glomerular filtration rate;
	BP: blood pressure; CKD: chronic kidney disease.</p>
	
	* The SCORE categories for estimated 10-year risk for fatal cardiovascular events are based on sex, age, cholesterol level, systolic blood pressure, and smoking history, as defined by the 2016 European Society of Cardiology guidelines for cardiovascular disease <span class="nowrap_whitespace">progression.<sup>[1]</sup></span></div><div class="graphic_reference">Reference:
	<ol>
<li>Piepoli MF, Hoes AW, Agewa S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J 2016; 37:2315.</li>
</ol>
<p class="extra_spacing_top">Reprinted by permission from Springer: Heart Failure Reviews. Casavecchia G, Galderisi M, Novo G, et al. Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib. Heart Fail Rev 2020; 25:447. Copyright © 2020. <a href="https://www.springer.com/journal/10741" target="_blank">https://www.springer.com/journal/10741</a>.</p></div><div id="graphicVersion">Graphic 134830 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
